Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Apixaban
Drug ID BADD_D00151
Description Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].
Indications and Usage Apixaban is to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It has also been used to lower the risk of developing venous thrombosis post-orthopedic surgical procedures.
Marketing Status Prescription
ATC Code B01AF02
DrugBank ID DB06605
KEGG ID D03213
MeSH ID C522181
PubChem ID 10182969
TTD Drug ID D0I5HF
NDC Product Code 0003-0893; 65129-1344; 55111-980; 50193-0893; 63629-8432; 16436-0113; 70366-001; 46708-908; 52048-0420; 63850-8085; 42816-0893; 14445-150; 59651-051; 53747-062; 65015-897; 55154-0613; 66174-0091; 76397-007; 75945-060; 24196-190; 15308-1221; 12783-0894; 66651-921; 63415-0520; 70518-1861; 66039-925; 65372-1196; 55154-0612; 12783-0893; 69989-0006; 76397-010; 42765-025; 76072-1017; 14501-0089; 67835-0015; 69037-0023; 50090-1437; 0003-0894; 58623-0137; 0003-3764; 42816-0894; 67296-1673; 58032-2028; 50090-1436; 65727-081; 14445-014; 63629-7747; 14445-149
Synonyms apixaban | Eliquis | BMS 562247 | BMS562247 | BMS-562247-01 | BMS-562247
Chemical Information
Molecular Formula C25H25N5O4
CAS Registry Number 503612-47-3
SMILES COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Feeling jittery08.01.09.016--Not Available
Femoral neck fracture15.08.03.002; 12.04.01.0020.003974%Not Available
Femur fracture15.08.03.003; 12.04.01.003--Not Available
Fibrin D dimer increased13.01.02.0360.001987%Not Available
Flank pain15.03.04.003; 08.01.08.007; 20.02.03.0060.001192%
Flatulence07.01.04.002--
Fluid overload14.05.06.001; 02.05.04.004--Not Available
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Flushing23.06.05.003; 08.01.03.025; 24.03.01.002--
Folliculitis23.09.04.007; 11.01.12.018--
Foot fracture15.08.03.012; 12.04.01.012--Not Available
Fracture15.08.02.001; 12.04.02.0010.005961%
Frequent bowel movements07.02.04.002--Not Available
Fungal infection11.03.05.001--Not Available
Gait disturbance08.01.02.002; 17.02.05.016--
Gallbladder disorder09.03.02.001--Not Available
Gamma-glutamyltransferase increased13.03.01.011--
Gangrene24.04.05.003; 23.06.06.001; 11.02.01.003--Not Available
Gastric cancer16.13.03.001; 07.21.02.0010.001002%Not Available
Gastric haemorrhage07.12.01.001; 24.07.02.0070.015235%
Gastric polyps16.05.03.001; 07.20.01.0030.000397%Not Available
Gastric ulcer07.04.03.0020.006226%
Gastric ulcer haemorrhage24.07.02.003; 07.04.03.0050.002120%Not Available
Gastritis07.08.02.0010.003179%
Gastritis erosive07.04.03.0030.001325%Not Available
Gastritis haemorrhagic24.07.02.008; 07.08.02.0020.000530%Not Available
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis11.01.07.004; 07.19.03.0010.001457%Not Available
Gastrointestinal carcinoma16.13.04.001; 07.21.03.0010.000311%Not Available
Gastrointestinal disorder07.11.01.0010.011261%Not Available
The 11th Page    First    Pre   11 12 13 14 15    Next   Last    Total 45 Pages